GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2009

Astellas Pays $40M Up Front to Develop Ambit’s FLT3 Kinase Inhibitors

  • Ambit Biosciences is receiving an up-front payment of $40 million as part of its agreement with Astellas Pharma related to FLT3 kinase inhibitors in oncology and nononcology indications. Precommercialization milestone fees under the worldwide development and commercialization deal could reach $350 million.

    The partnership covers AC220, Ambit’s lead drug, which is in a Phase II trial covering relapsed/refractory acute myeloid leukemia (AML) patients.  The companies will collaborate to develop the compound for AML as well as other indications. They will also conduct R&D on additional FLT3 inhibitors.

    The firms will share equally in the responsibilities and expenses of developing all products in the U.S. and Europe. Astellas has sole responsibility to fund development in all other territories.

    Astellas will handle commercialization of all products, including funding. Ambit will be entitled to postapproval milestone payments upon the achievement of certain sales thresholds as well as tiered double-digit royalties on net sales. In the U.S. Ambit will also have the option to co-promote AC220 and other products. If exercised, Astellas and Ambit will share equally in profits and losses generated from U.S. sales.

    AC220 is an orally available, potent, and highly selective small molecule that was designed as a second-generation FMS-like tyrosine kinase-3 inhibitor using Ambit’s discovery engine, KINOMEscan™.

    The Phase II trial is designed to support potential registration of AC220 as monotherapy treatment in adult and elderly patients with relapsed/refractory AML that have the internal tandem duplication mutation in the FLT3 kinase. The FLT3 kinase is mutated and constitutively activated in 25–40% of such patients, according to Ambit.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »